MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.54
+0.24
+1.39%
Opening 10:23 04/23 EDT
OPEN
17.36
PREV CLOSE
17.30
HIGH
17.54
LOW
17.34
VOLUME
3.32K
TURNOVER
--
52 WEEK HIGH
23.70
52 WEEK LOW
11.61
MARKET CAP
659.12M
P/E (TTM)
-7.1666
1D
5D
1M
3M
1Y
5Y
Crinetics Pharmaceuticals Stock Is Showing Strong Insider Interest
Clinical-stage pharmaceutical company Crinetics Pharmaceuticals Inc. (CRNX) has seen a key corporate insider snap up shares recently. Regulations require corporate ins...
TipRanks.com · 2d ago
Crinetics Pharmaceuticals Announces Closing of Common Stock Offering
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrin...
GlobeNewswire · 04/12 20:05
What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?
A look at the shareholders of Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) can tell us which group is most powerful...
Simply Wall St. · 04/12 07:32
Insider Buys Crinetics Pharmaceuticals Shares
 
Benzinga · 04/09 15:18
DJ Crinetics Pharmaceuticals Shares Rise 15% After Public Offering Prices
Dow Jones · 04/08 17:43
Auris Medical, Prometheus Biosciences leads healthcare gainers; Endo International, Odonate Therapeutics among major losers
Gainers: Auris Medical (EARS) +18%, Prometheus Biosciences (RXDX) +15%, Crinetics Pharmaceuticals (CRNX) +13%, Genprex (GNPX) +12%, Fortress Biotech (FBIO) +12%.Losers: Endo International (ENDP) -10%, Odonate Therapeutics (ODT) -9%, Otonomy (OTIC) -8%, Bro...
Seekingalpha · 04/08 15:05
Crinetics Pharmaceuticals Wednesday Announced Pricing Of Public Offering Of ~4.56M Shares Of Common Stock At $16.44/Share
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and
Benzinga · 04/08 13:20
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7)
Benzinga · 04/08 12:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRNX. Analyze the recent business situations of Crinetics Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRNX stock price target is 32.00 with a high estimate of 42.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 111
Institutional Holdings: 32.38M
% Owned: 86.16%
Shares Outstanding: 37.58M
TypeInstitutionsShares
Increased
33
2.68M
New
20
613.13K
Decreased
15
2.82M
Sold Out
6
380.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.20%
Pharmaceuticals & Medical Research
+0.24%
Key Executives
Chairman/Independent Director
Wendall Wierenga
President/Chief Executive Officer/Director
R. Scott Struthers
Chief Financial Officer
Marc Wilson
Vice President/Director of Human Resources
Adriana Cabre
Vice President
Peter Trainer
Other
Alan Krasner
Other
Ajay Madan
Independent Director
Camille Bedrosian
Independent Director
Matthew Fust
Independent Director
Stephen Kaldor
Independent Director
Weston Nichols
Independent Director
Stephanie Okey
No Data
  • All
  • Financials
  • Insiders
More
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.

Webull offers kinds of Crinetics Pharmaceuticals Inc stock information, including NASDAQ:CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.